ABOUT US
At Diaceutics we believe that every patient should have access to the right treatment at the right time to positively impact their disease outcome, and we are committed to solving commercialization challenges.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine through our platform
DXRX - The Diagnostic Network®
Copyright © 2024, Diaceutics. All rights reserved
ESMO CONGRESS
MEET US AT
Berlin, Germany
17-21 October
Our team will be attending ESMO from 17–21st October in Berlin, Germany.
Set your launch strategy up for success with early analysis
2025
Schedule a meeting with one of our solution experts to explore how Diaceutics is uniquely positioned to help you achieve commercialization success for your precision medicine:
Contact Us to Schedule a Meeting
Discover where patients are being lost between testing and treatment - and how to close those gaps using our Practice Gaps Identifier.
Engage labs effectively: reach clinical labs and pathologists with targeted, science-based campaigns through DXRX Lab Engage to maximize biomarker testing rates
Launch with confidence with our 6A™ Strategic Landscape, combining expert analysis with real-world testing insight to uncover what’s slowing adoption and how to fix it.
Schedule a meeting with one of our solution experts at ESMO
CLIENT DIRECTOR
DOMAIN EXPERT
TEssa Sandberg
Colin Clarke
RORY WILKINSON
CLIENT DIRECTOR
CONOR STEELE
CLIENT DIRECTOR
CLIENT DIRECTOR
Lyam Buchanan
CLIENT DIRECTOR
Rachael Hewitt
Poster presentation
On Saturday the 18th of October, Tessa Sandberg, Domain Expert at Diaceutics, will present research at ESMO which highlights the impact of testing models on patient access to personalized therapy in advanced non-small cell lung cancer (aNSCLC).
Impact of molecular test result report and its turnaround time (TAT) on patient's access to personalized therapy in advanced non-small cell lung cancer (aNSCLC): a comparative study between Italy and the UK
Many therapies stall at launch because the right focus areas were not addressed early enough. Our 6A™ Precision Medicine Strategic Landscape identifies where your diagnostic strategy may be weaker enabling you to react and adapt your strategy to maximize patient access.
Gain a critical understanding of every stage of your commercial launch utilizing our proprietary framework designed to address the key pilars to success: Awareness, Adoption, Access, Availability, Accuracy, and Action
Understand where testing, engagement, or access efforts may be limiting launch excellence
High-level strategy doesn’t guarantee impact. Our Tactical Playbooks give you a custom, execution ready plan laying out exactly what to do, when to do it, and how to measure success:
A tactical roadmap that ensures every action drives adoption
Translate strategic frameworks into prioritized, Time phased actions with the right KPI s to track progress
Focus only on high-impact tactics backed by real-world results
Cross-functional by design- Build testing, access, and HCP engagement into a single, coordinated plan
Focus your teams and budget on interventions that actually improve adoption
Reach clinical laboratories and pathologists with targeted, science-based marketing strategies that drive precision medicine adoption with DXRX Lab Engage
From pre-analytical considerations through result interpretation, our targeted campaigns ensure your precision medicine testing reach decision-makers at critical implementation points
Pinpoint where are being lost between test and treatment to maximize patient access to therapy
Patients are often missed along the treatment pathway. Diaceutics Practice Gaps Identifier shows you exactly where these patients are being missed and equips you with a plan to close these gaps. Built on multi-modal data and expert insight, we highlight the 7 practice gaps that limit uptake and patient access enabling you to:
Identify breakdowns between testing, diagnosis, and prescribing
Replace assumptions with real-world insight
Diana Hernandez Quintero
PRECISION MEDICINE STRATEGY ADVISOR
PRECISION MEDICINE STRATEGY ADVISOR
HELEN SADIK
